Online citations, reference lists, and bibliographies.
← Back to Search

Use Of A Mouse Lung Challenge Model To Identify Antigens Protective Against Chlamydia Pneumoniae Lung Infection.

A. Murdin, P. Dunn, R. Sodoyer, J. Wang, J. Caterini, R. Brunham, L. Aujame, R. Oomen
Published 2000 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Chlamydia pneumoniae is emerging as a significant human pathogen. Infection causes a range of respiratory tract diseases and is associated with atherosclerosis. A vaccine could provide a considerable public health benefit; however, antigens able to elicit a protective immune response are largely unknown. A panel of open-reading frames (ORFs) from the C. pneumoniae genome sequence was screened for ability to elicit protective responses. Balb/c mice immunized with DNA containing the ORFs were tested for their ability to limit lung infection following an intranasal challenge. Immunization with DNA encoding the major outer membrane protein or an ADP/ATP translocase (Npt1(Cp)) of C. pneumoniae resulted in a reduced bacteria load in the lung after challenge. The identification of these antigens as protective is a significant step toward development of a C. pneumoniae vaccine and demonstrates the feasibility of using a DNA immunization strategy to screen the C. pneumoniae genome for other protective ORFs.
This paper references
10.1016/S0140-6736(88)90741-6
SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION
P. Saikku (1988)
10.1093/INFDIS/161.4.618
A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR
J. T. Grayston (1990)
10.1001/JAMA.1991.03470020051031
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.
D. Hahn (1991)
10.1128/MMBR.55.1.143-190.1991
Interaction of chlamydiae and host cells in vitro.
J. Moulder (1991)
10.1001/JAMA.1992.03490010070032
Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease.
D. Thom (1992)
10.7326/0003-4819-116-4-273
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
P. Saikku (1992)
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques.
A. Shor (1992)
10.1161/01.ATV.13.10.1501
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain.
C. C. Kuo (1993)
10.1093/INFDIS/167.4.841
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.
C. C. Kuo (1993)
10.1093/INFDIS/168.5.1231
Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.
J. T. Grayston (1993)
10.1183/09031936.94.07122165
Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection.
L. Allegra (1994)
10.1128/iai.62.3.880-886.1994
Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope
M. Perez Melgosa (1994)
10.1128/CMR.8.4.451
Chlamydia pneumoniae (TWAR)
C. Kuo (1995)
10.1111/j.1699-0463.1995.tb01436.x
The immunobiology and immunopathology of chlamydial infections
M. E. Ward (1995)
10.1002/jlb.58.1.1
Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases
Marion E. Perkvs (1995)
10.7326/0003-4819-125-12-199612150-00008
Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis
Julio Ramirez (1996)
Chlamydia pneumoniae and chronic lung diseases.
A. Laurila (1997)
10.1089/AID.1997.13.1421
Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1.
N. Ishii (1997)
10.1086/516545
DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection.
D. Zhang (1997)
10.1016/S0741-5214(97)70143-5
Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction.
C. C. Kuo (1997)
10.1046/j.1365-2567.1997.00307.x
HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody
S. Toda (1997)
10.1161/01.CIR.96.7.2144
Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery.
B. Chiu (1997)
10.1016/S0264-410X(96)00278-2
Mucosal immunization with DNA-liposome complexes.
L. Klavinskis (1997)
10.1128/cdli.4.6.700-704.1997
Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae
M. Wiedmann-Al-Ahmad (1997)
10.1086/517270
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.
L. Jackson (1997)
10.1016/S1081-1206(10)62938-9
Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma.
D. Hahn (1998)
10.3201/EID0404.980407
Chlamydia pneumoniae and cardiovascular disease.
L. Campbell (1998)
10.1128/JVI.72.7.5757-5761.1998
Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles
Shing C. Chen (1998)
10.1016/S0735-1097(98)00016-3
Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.
M. Maass (1998)
10.1038/NM0498-397
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
J. Schneider (1998)
10.1073/PNAS.95.13.7648
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.
M. Sedegah (1998)
10.1128/IAI.66.11.5113-5118.1998
Local Immune Responses to Chlamydia pneumoniae in the Lungs of BALB/c Mice during Primary Infection and Reinfection
Jenni M. Penttilä (1998)
10.1128/JVI.72.12.10180-10188.1998
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
S. Kent (1998)
10.1097/00002030-199818000-00009
Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers
R. Belshe (1998)
10.1128/IAI.67.1.375-383.1999
Identification of Two Novel Genes Encoding 97- to 99-Kilodalton Outer Membrane Proteins of Chlamydia pneumoniae
K. Knudsen (1999)
10.1089/088922299310935
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
D. Salmon-Céron (1999)
10.1128/JB.181.4.1196-1202.1999
Two Nucleotide Transport Proteins in Chlamydia trachomatis, One for Net Nucleoside Triphosphate Uptake and the Other for Transport of Energy
J. Tjaden (1999)
10.1086/314895
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
T. Evans (1999)
Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice.
M. Rottenberg (1999)
10.1038/8406
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
H. Robinson (1999)
10.1046/j.1365-2567.1999.00682.x
Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain
Zhang (1999)
10.1046/j.1365-2567.1999.00809.x
Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice
Penttilä (1999)
10.1038/7716
Comparative genomes of Chlamydia pneumoniae and C. trachomatis
S. Kalman (1999)
10.1093/CLINIDS/18.4.501
[Community acquired pneumonia].
T. Marrie (2001)



This paper is referenced by
10.1080/14760584.2018.1435279
Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles
Rajnish Sahu (2018)
10.1016/j.ijcard.2012.05.098
Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions.
D. Pedicino (2013)
Vaccination against chlamydial and mycobacterial infections Ph
Á. Szabó (2013)
10.1159/000348762
Chlamydia Vaccine Development
J. Igietseme (2013)
10.1007/978-1-4615-0105-3_10
DNA Vaccines against Bacterial Pathogens
M. Chambers (2013)
10.1128/9781555817329.CH13
In Vivo Chlamydial Infection
R. Rank (2012)
10.1128/9781555817329.CH14
Chlamydia vaccine: progress and challenges.
A. Murthy (2012)
Comprehensive analysis of the impact of endemic Chlamydia pecorum infection in cattle
Anil Poudel (2012)
10.2165/00063030-200216010-00003
Chlamydia Vaccines
J. Igietseme (2012)
10.1586/erv.11.139
Chlamydia vaccines: recent developments and the role of adjuvants in future formulations
J. Igietseme (2011)
10.1556/AMicr.58.2011.2.5
Vaccination with DNA vector expressing chlamydial low calcium response protein E (LcrE) against Chlamydophila pneumoniae infection.
Ildikó Faludi (2011)
10.1016/j.vaccine.2009.11.046
Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.
Y. Li (2010)
10.1111/j.1472-8206.2010.00863.x
Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis
J. Deniset (2010)
10.1111/j.1574-695X.2008.00519.x
Innate immunity and vaccines in chlamydial infection with special emphasis on Chlamydia pneumoniae.
M. Puolakkainen (2009)
10.1586/erv.09.98
Chlamydia vaccine candidates and tools for chlamydial antigen discovery
D. Rockey (2009)
Genital tract CD4 + T cells for vaccination and protection against Chlamydia trachomatis
Ellen Marks (2009)
10.1042/CS20070298
Role of Chlamydia pneumoniae in atherosclerosis.
C. Watson (2008)
10.1086/525045
Chlamydophila pneumoniae inhibits differentiation of progenitor adipose cells and impairs insulin signaling.
Y. Shi (2008)
10.1038/mi.2007.19
Chlamydia trachomatis infection: host immune responses and potential vaccines
L. Hafner (2008)
Therapeutic vaccines against chlamydial diseases
Y. Li (2008)
10.1007/978-1-4020-8412-6_16
Immunity Against Chlamydia trachomatis
E. Marks (2008)
10.1111/j.1365-2567.2007.02608.x
Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
Q. He (2007)
10.2217/17460913.2.3.219
Reducing the risk of Chlamydia trachomatis transmission: male circumcision or a female vaccine?
L. Hafner (2007)
10.1016/J.VACCINE.2006.12.003
Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection.
Callum Thorpe (2007)
10.1016/J.VACCINE.2005.12.035
Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates.
D. Li (2006)
10.1586/14760584.5.6.739
Combination vaccines: design strategies and future trends
J. Igietseme (2006)
10.3402/ijch.v65i2.18097
Experimental Chlamydia pneumoniae infection model: Effects of repeated inoculations and treatment
L. Törmäkangas (2006)
Innate immune responses induced by Chlamydia pneumoniae infection
V. Magdalenić (2005)
10.1016/b978-012491543-5/50104-2
Maternal Genital Tract Infection and the Neonate
D. Tristram (2005)
PULMONAR Y INFECTION A ND A T HEROSCLEROSIS IN A N EXPERIMENT A L CHLAMYDIA PNEUMONIAE MODEL
L. Erkkilä (2005)
10.1007/0-306-48741-1_8
Vaccines Against Chlamydia pneumoniae: Can They Be Made?
M. Rottenberg (2005)
CD8+ T Cell Response in Experimental Chlamydia pneumoniae Infection
A. Tammiruusu (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar